Status:
COMPLETED
Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion
Lead Sponsor:
Centre Hospitalier Intercommunal Creteil
Conditions:
Central Retinal Vein Occlusion
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare ranibizumab injection to hemodilution at the early phase of Central Retinal Vein Occlusion (CRVO) and to determine if the combination of both treatments may hav...
Detailed Description
Patients with recent-onset CRVO (lasting for less than 1 month)are randomly assigned to one of 3 groups: hemodilution using erythrocytapheresis alone, 3 monthly injection of ranibizumab alone, or both...
Eligibility Criteria
Inclusion
- CRVO confirmed by fluorescein angiography
- duration from onset of 1 month or less
- visual acuity of 20/32 or less
Exclusion
- neovascular complication
- extensive retinal ischemia requiring prompt panretinal photocoagulation
- hematocrit level lower than 38%
- previous laser or surgery in the study eye, etc
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT01448018
Start Date
January 1 2010
End Date
December 1 2013
Last Update
August 13 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Intercommunal Hospital
Créteil, France, 94000
2
Pitie-Salpetriere Hospital
Paris, France, 75013